Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study

Masahiro Takeshima,1 Hiroyasu Ishikawa,2 Takashi Kanbayashi,1 Tetsuo Shimizu3 1Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita City, Akita 010-8543, Japan; 2Department of Neuropsychiatry, Nakadori Rehabilitation Hospital, Akita City, Akita 010-0001, Japan; 3Akita...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takeshima M, Ishikawa H, Kanbayashi T, Shimizu T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	akathisia antipsychotic agents gabapentin enacarbil restless legs syndrome schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/a604554dfb0043978cd326cd1be7799c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a604554dfb0043978cd326cd1be7799c
record_format	dspace
spelling	oai:doaj.org-article:a604554dfb0043978cd326cd1be7799c2021-12-02T03:19:30ZGabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study1178-2021https://doaj.org/article/a604554dfb0043978cd326cd1be7799c2018-11-01T00:00:00Zhttps://www.dovepress.com/gabapentin-enacarbil-for-antipsychotic-induced-akathisia-in-schizophre-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Masahiro Takeshima,1 Hiroyasu Ishikawa,2 Takashi Kanbayashi,1 Tetsuo Shimizu3 1Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita City, Akita 010-8543, Japan; 2Department of Neuropsychiatry, Nakadori Rehabilitation Hospital, Akita City, Akita 010-0001, Japan; 3Akita Prefectural Mental Health and Welfare Center, Akita City, Akita 010-0001, Japan Objective: Gabapentin and its prodrug are candidate therapeutic agents for akathisia. An open-label pilot study was conducted to investigate the therapeutic potential of gabapentin enacarbil (GE) for akathisia.Methods: In an open-labeled investigator-initiated clinical trial, nine outpatients with antipsychotics-induced akathisia were administered GE (300 or 600 mg/day) over 2 weeks. The BARS global akathisia score was used to assess akathisia. The BPRS was used to assess psychiatric symptoms. The subjects were also systematically questioned regarding the adverse events described in an interview form following GE treatment. An intension-to-treat analysis including all patients enrolled in the present study was completed.Results: One patient declined to participate further in the study on the third day after the start of treatment. Eight patients thus completed the entire trial (male: 2, female: 6, age [mean±SD]: 38.8±11.6 years). The average dosage of GE was 567 mg/day (300 mg/day [n=1], 600 mg/day [n=8]). The BARS global akathisia score significantly decreased after 1 and 2 weeks of treatment when compared to baseline (P=0.01 and P=0.01, respectively). There were no significant differences in BPRS score 1 or 2 weeks after the start of treatment. No serious adverse events occurred.Conclusion: GE has therapeutic potential for antipsychotics-induced akathisia. No additional risk of GE use for the management of akathisia was indicated. Keywords: clinical trial, antipsychotic agents, restless legs syndrome, schizophrenia Takeshima MIshikawa HKanbayashi TShimizu TDove Medical Pressarticleakathisiaantipsychotic agentsgabapentin enacarbilrestless legs syndromeschizophreniaNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 3179-3184 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	akathisia antipsychotic agents gabapentin enacarbil restless legs syndrome schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	akathisia antipsychotic agents gabapentin enacarbil restless legs syndrome schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Takeshima M Ishikawa H Kanbayashi T Shimizu T Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
description	Masahiro Takeshima,1 Hiroyasu Ishikawa,2 Takashi Kanbayashi,1 Tetsuo Shimizu3 1Department of Neuropsychiatry, Akita University Graduate School of Medicine, Akita City, Akita 010-8543, Japan; 2Department of Neuropsychiatry, Nakadori Rehabilitation Hospital, Akita City, Akita 010-0001, Japan; 3Akita Prefectural Mental Health and Welfare Center, Akita City, Akita 010-0001, Japan Objective: Gabapentin and its prodrug are candidate therapeutic agents for akathisia. An open-label pilot study was conducted to investigate the therapeutic potential of gabapentin enacarbil (GE) for akathisia.Methods: In an open-labeled investigator-initiated clinical trial, nine outpatients with antipsychotics-induced akathisia were administered GE (300 or 600 mg/day) over 2 weeks. The BARS global akathisia score was used to assess akathisia. The BPRS was used to assess psychiatric symptoms. The subjects were also systematically questioned regarding the adverse events described in an interview form following GE treatment. An intension-to-treat analysis including all patients enrolled in the present study was completed.Results: One patient declined to participate further in the study on the third day after the start of treatment. Eight patients thus completed the entire trial (male: 2, female: 6, age [mean±SD]: 38.8±11.6 years). The average dosage of GE was 567 mg/day (300 mg/day [n=1], 600 mg/day [n=8]). The BARS global akathisia score significantly decreased after 1 and 2 weeks of treatment when compared to baseline (P=0.01 and P=0.01, respectively). There were no significant differences in BPRS score 1 or 2 weeks after the start of treatment. No serious adverse events occurred.Conclusion: GE has therapeutic potential for antipsychotics-induced akathisia. No additional risk of GE use for the management of akathisia was indicated. Keywords: clinical trial, antipsychotic agents, restless legs syndrome, schizophrenia
format	article
author	Takeshima M Ishikawa H Kanbayashi T Shimizu T
author_facet	Takeshima M Ishikawa H Kanbayashi T Shimizu T
author_sort	Takeshima M
title	Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
title_short	Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
title_full	Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
title_fullStr	Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
title_full_unstemmed	Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
title_sort	gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/a604554dfb0043978cd326cd1be7799c
work_keys_str_mv	AT takeshimam gabapentinenacarbilforantipsychoticinducedakathisiainschizophreniapatientsapilotopenlabeledstudy AT ishikawah gabapentinenacarbilforantipsychoticinducedakathisiainschizophreniapatientsapilotopenlabeledstudy AT kanbayashit gabapentinenacarbilforantipsychoticinducedakathisiainschizophreniapatientsapilotopenlabeledstudy AT shimizut gabapentinenacarbilforantipsychoticinducedakathisiainschizophreniapatientsapilotopenlabeledstudy
_version_	1718401813230649344

Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study

Ejemplares similares